Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

Roast bear

Ingredients
500 g bear flesh
7 ea pork lard pieces
1 tb butter
1/2 c marinade (see the recipe of Marinade for Wild-Game)
greens
salt


Method
Wash the meat carefully, lard every slice lengthwise. Keep in marinade for 8-10 hours, turning regularly. Salt if needed. Put on a baking sheet, add a little of marinade, pour over melted butter and bake in well heated oven, sprinkling with meat juice regularly, for 2-2.5 hours.

Hello All

I have not been on for a chat for some time
started a new (day) job and thats keept me busy (having fun too)

i(we all) are taking a bit of a hit on old, BPRG

but as i said many times before

you havent won or lost a bean until you sell

I still have BPRG as a strong long term buy

I am holding (i'd buy at this price, but i have too much out at the moment)

have a look at BDH,SLY,DAG,CHG,BKL,LWB,CDW,LAS

my best tip 'Premium Bonds' (dont overlook this invest op)

good luck all,

:o)
aqa

goldfinger-Hi,are you still holding bprg ? would like an honest view on this share-as so many confusing posts.

Thanks in advance

ep

aquafresh,


"you havent won or lost a bean until you sell"

LOL!

I hope you aren't being serious!

Citywire says BPRG is up today on bid rumours.

Citywire says BPRG is up today on bid rumours.

gf-please reply to post 524

Gf,where the hell are you.Please reply to emails.Thanks.News abound what with the imminent bid.Fill yer boots,shorters fry!!!!

With respect, if you have all done your own research and are happy with it, why do you need Goldfinger to hold your hand? If he says he's been stopped out, are you going to sell? Get a grip guys - what do you really believe?

my request bones was more personal with GF rather than to do with BPRG but I agree with your views.GF is not in charge,it's GH!!!!!!!

Some news on ADVFN site via BB check the link

http://www.advfn.com/cmn/fbb/thread.php3?id=6441092

A turning point ahead, maybe ?

Cant get the link can you give us an idea what this news is? Is this affecting the price today? Thanks in advance.

From the ramblings


davidcod - 25 May'04 - 16:20 - 19331 of 19388
WELL WELL WELL.. some news for you shorters out there...
remember ISP UK?? the company rumoured to have tabled a bid @ 1.20??
well I have just been informed that Graham Hind had a meeting last Friday with the head of ISP UK..
its all falling into place quite nicely..
enjoy while you can..


2kpromoe - 25 May'04 - 16:22 - 19335 of 19388
Davidcod---> lol! just heard exactly the same myself young man, news does travel fast! takeover bid still on course maybe, wonder what price? 1.50, 2, 3???


belabed - 25 May'04 - 16:31 - 19347 of 19391
Davidcod,
Your a bit behind with your info mate, some on here knew about it the day it was happening!


davidcod - 25 May'04 - 16:36 - 19356 of 19391
ISP originally tabled a bid of 1.20, BPRG rejected this
Perhaps ISP were unaware of the contract with w***h, hence the reason BPRG rejected, and are now willing to fork out more cash for the company??


Sir Moles Molson - 25 May'04 - 17:48 - 19398 of 19412
makday,
How do you know GH turned down an actual offer of 120p? Is this published information or just another rumour?


makday - 25 May'04 - 17:49 - 19399 of 19412
A very well known piece of info within the city fraternity.

Thanks for the details will await more info, would hope for alot more than 1.20 per share but lets wait and see if these rumours turn into something more substantial. Thanks for down loading grot.

If all else fails .... start a takeover rumour.

Dil,

LOL!

Many a true word spoken in jest!

More from the ramblings;

powderman - 27 May'04 - 01:28 - 20211 of 20215

I have been watching from the sidelines for some time and I have wondered whether the people on this board really do care about this stock.It's not often you come across a small company with such mind boggling technology.My apologies to all those who have bought this stock for a long term view,I assure you that you will be rewarded.I am not going to go through all the deals like FMC,swallow etc for you will have read and reread the possibilities and endless bounties associated with all those deals.Graham is working tooth and nail to get you the shareholders the best deals,yes I repeat the best deals he can deliver.He is a very very shrewd fellow and he will not sell you down the river though lately on several occassions he has told me he's not happy with the conduct of some of the shareholders and at times has been rather abrupt with some of the shareholders.Graham is not impertinent by any stretch of the imagination but has been terribly served by short term traders and dare I say it by the shorters.Nothing in life comes easy so please show patience and try not to look for RNS'S,brokers notes every hour of every day.It is true alot is happenning in the background and yes some of it has leaked out like the meeting with CS today.There are others who have come into the equation of which you have heard of ISP but believe me there are much bigger players after BPRG who probably will pay a bigger premium to the current shareprice.Let the management get on with it's function and don't fret, for all will come good in time and alot sooner than most of you people think.
Right I'm off now and I'll see you guys after all the good news has appeared.

excellent post from RON,


I recently asked a few questions regarding Malcolm's resignation as a director just to clarify the situation for others,as I knew the truth by reading previous announcements on the situation,but obviously getting it across to others was not easy.
This is a mail direct to me about the situation and other comments from Barry J. Muncaster HIMSELF.

RON

Dear Ron.

Thank you for your email regarding BPRG's recent RNS, which was forwarded to
me by BPRG's email system. I no longer use my old BPRG email address because
my consultant agreement completed on April 30th of this year. And before you
ask, no, it was not a reportable event. So please respond to this address if
you feel the need to do so.

Other than being a shareholder and responsible for management of the
litigation with Stanelco (which does not make me an insider) I am no longer
privy to events at BPRG. So any comment I make or opinion I give is entirely
my own.

With regard to the RNS announcing Malcolm's resignation as a director, you
are not alone in having contacted me for my comments. Frankly, I am quite
surprised by the amount of discussion and concern that it caused. It has
been public knowledge for a year that Malcolm had given up his full time
executive role, serving only as a consultant for 3 days a week whilst
retaining his seat on the board by virtue of his quite large shareholding
and because the board needed his vast experience whilst putting together the
technical team required to maximise the commercial benefit of his many
ideas. Friday's announcement was no more and no less than confirmation of
that long held intent.

It would seem that some shareholders are interpreting "immediate effect" to
mean a boardroom bust up or dispute. Nothing could be further from the
truth. I know Malcolm and Graham very well and consider them close and
valued friends. I also know the other board members quite well. There is no
dispute and there has been no bust up. The reason for Malcolm resigning with
immediate effect is quite simple; that's how it's done and that's how it
should be announced. More importantly, Malcolm has helped put in place a
superb technical team who are more than competent to enable the Company to
reach its commercial goals.

In my view, and this view is shared by many in the City, the PLC board
should made up by no more than 4 or 5 high quality and experienced
individuals who together provide the guidance and resources necessary for
the CEO it execute its strategy. We have such a board and it has not been
weakened by Malcolm's resignation. In the last few months we've seen Stephen
Lee appointed as Engineering Director of BTL (BPRG's operating subsidiary)
and Beth Edwards appointed as BTL's Financial Director. In addition, BPRG
has acquired Aquafilm, which is ably run by Scott Schaneville supported by
around 30 staff, of whom most are technically qualified. Ian Thompson
continues to be BTL's Operations Director and Dr. Jason Teckeo heads up film
development whilst Ed Nowak continues essential research into new materials
and applications. Couple all of these skills and competence with those of HH
plus support and initiatives from the engineers and scientists of the
Company's customers and you have a pretty impressive ensemble for such a
small and emerging Company. In short, we have a board that attends to the
needs of the PLC's business with operating subsidiaries that are well
manned, well resourced and most able to deliver on the Company's promises.

Frankly, anyone who thinks BPRG is a one-man business, needs to think again!

I've received many emails complaining about BPRG's apparent lack of quality
PR. Whilst respecting the views of all shareholders - it is their company
after all - I do wish people would stand back for a moment and take in the
full picture. First, let's differentiate between PR (Public Relations) and
IR (Investor Relations). BPRG doesn't need PR. Why? Many reasons, but here's
a couple for starters. First, it doesn't deal with the public, its customers
do and it will be their responsibility to inform and educate end users about
the benefits of XGel at the appropriate time. Does anyone really think for
one minute that major global pharmaceutical companies (who represent BPRG's
customer base) want BPRG out there saying things about XGel before it's
commercially available and in doing so possibly spoiling opportunities in
the market? Second, PR is most often used to attract potential customers to
a company's products and services. In BPRG's case it doesn't need, nor could
it handle any more customers at present; so why spend time, energy and
resources attracting customers who BPRG couldn't satisfy? For goodness sake,
BPRG already has a full compliment of world class customers and in my
opinion it should (and is) concentrate solely on satisfying the needs of its
current customers. Has everyone forgotten the work that's going on with
other yet to be named pharma companies as well as progress with Farmasierra?
I've had comments passed to me about notes written by Scrutable who is
somewhat disappointed that HH will not be exhibiting XGel machines at
conferences. Notwithstanding Scrutable's prior work experience, his views in
this regard show a distinct lack of understanding of BPRG's business model.
BPRG does not want to show its systems to every Tom, Dick or Harry; it
already has its customer base. Why show your technology to all and sundry
and for free? I would understand Scrutable's view if BPRG's offering was a
standard type of production machine, but it isn't. The sale of an XGel
system is a complex process involving licensing of intellectual property,
machine supply, warranty and support, and most importantly film supply. You
don't just place an XGel system on an exhibition booth and wait to see what
or who turns up! BPRG knows who its customers are and is dealing with them;
end of story.

With regard to IR, what would you have the Company do? During its first year
listed on AIM it has provided the market with a good stream of news flow and
some of the announcements have been quite outstanding given that BPRG is a
small UK based company that is pioneering a revolution in a massive and
mature global market. It has kept the market informed of all material
developments and in interviews Graham has explained his vision for the
Company and progress to that end. Announcements may have been worded
differently, but had they been so then I'm sure someone would have found
fault, regardless. Discontent with the wording of statements; delays in
execution of deals; and, delays in the appearance of broker notes is an
understandable reaction, but such should not be of real concern to those
shareholders who have a medium/long term view about the Company's prospects.

Much criticism has been levelled at Collin Stewart. Quit unfairly in my
view. CS has raised funds at 16p, 70p and 110p all within the space of a few
months and in trying market conditions. These funds have enabled the Company
to make massive strides and, most importantly, demonstrate to its major
customers its ability to stay in business and support them when they
introduce new technology to existing global brands as well as to new product
developments. Long term shareholders should value CS' contributions. I have
no doubt that the much talked about broker's note will appear in the not too
distant future.

I agree with general sentiment that the George Tidy affair was an IR foul
up. But, again, what was the Company to do about it? I know for certain that
BPRG has clean hands in the entire affair and that it did the right thing at
the right time. One cannot plan for every eventuality; sometimes things
don't go as planned and this was one such instance. The whole story will
become clear in due course.

I am a close friend of Graham's and I will do as you ask and have a word
with him about the concerns expressed by yourself and others.

Save for my email address, nothing in the email is confidential so please
feel free to disseminate it as you wish.

Sincerely,
Barry J. Muncaster

FMC BioPolymer and Farmasierra Establish Technology Development and Manufacturing Services Agreements for NRobe Dosage Form

FMC BioPolymer (FMC), a business unit of FMC Corporation (NYSE:FMC), has executed agreements with Grupo Farmasierra subsidiaries Farmasierra Manufacturing S.L. and Advanced Technology Pharma S.L. (Farmasierra), whereby Farmasierra will provide FMC with technology development and manufacturing services relating to the commercialisation of NRobe, a new oral dose form system employing pre-formed edible films in a dry, one-step process. Under these agreements, Farmasierra will work closely with FMC to support the development of NRobe technology for pharmaceutical applications. Farmasierra will be FMCs exclusive contract manufacturing partner for NRobe in Europe during the initial commercialization phase.

Robin Mitchell, Business Director responsible for new pharmaceutical technologies at FMC, said: Farmasierra has a reputation for superior quality contract manufacturing services and has assembled a highly qualified team to support its new focus on innovative product development services. By establishing these agreements, FMC expects to accelerate its development plans for NRobe and to be able to offer contract manufacturing services at the earliest possible stage. The enthusiasm of Tom Olleros and his team encourages us that NRobe has great potential and that we will be able to demonstrate significant benefits for pharmaceutical companies and patients through this technology. We have already established excellent working relationships between our companies.

We are delighted to be partnering with FMC in this way commented Dr. Tom Olleros, President of Grupo Farmasierra NRobe is an exciting new technology for making oral dose forms that fits well with Farmasierras desire to focus on innovative yet practical technologies. Quality, service and innovation are the key elements of our strategy for the future. To achieve this, we are partnering with well recognized and reliable companies to supply the pharmaceutical sector with added value technologies.

FMC announced the acquisition of an exclusive worldwide license for the NRobe dosage form, process, equipment and enabling technology from BioProgress (LSE:AIM:BPRG) on February 4, 2004. FMC has assumed full responsibility for the commercialization of NRobe and has a team of technical and commercial staff focused on NRobe development, primarily at its Princeton, New Jersey and Brussels, Belgium laboratories.

- Ends -

For further information:

FMC BioPolymer
Robin Mitchell, Director, New Pharmaceutical Business
Tel: + 1 215 299 5936
robin_mitchell@fmc.com
www.fmcbiopolymer.com

Farmasierra Manufacturing S.L. &
Advanced technology Pharma S.L
Tom Olleros, President
Tel: + 34 916 570 659
tomas@farmasierra.com
www.farmasierra.com



http://www.fmcbiopolymer.com/Biopolymer/V2/BIONewsDetail/0,1418,2674,00.html

A very interesting article by Wendy Durham. Worth a read.

http://www.fillyaboots.com/?mount=Frames/whatwe.html